141 related articles for article (PubMed ID: 24627237)
1. Quality of life in patients with advanced gastric cancer sequentially treated with docetaxel and irinotecan with 5-fluorouracil and folinic acid (leucovin).
Gubanski M; Glimelius B; Lind PA
Med Oncol; 2014 Apr; 31(4):906. PubMed ID: 24627237
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial.
Gubanski M; Johnsson A; Fernebro E; Kadar L; Karlberg I; Flygare P; Berglund A; Glimelius B; Lind PA;
Gastric Cancer; 2010 Aug; 13(3):155-61. PubMed ID: 20820984
[TBL] [Abstract][Full Text] [Related]
3. An explorative randomised phase II study of sequential chemotherapy in advanced upper gastrointestinal cancer.
Berglund A; Byström P; Johansson B; Nygren P; Frödin JE; Pedersen D; Letocha H; Glimelius B
Med Oncol; 2010 Mar; 27(1):65-72. PubMed ID: 19212708
[TBL] [Abstract][Full Text] [Related]
4. Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer.
Bajetta E; Floriani I; Di Bartolomeo M; Labianca R; Falcone A; Di Costanzo F; Comella G; Amadori D; Pinto C; Carlomagno C; Nitti D; Daniele B; Mini E; Poli D; Santoro A; Mosconi S; Casaretti R; Boni C; Pinotti G; Bidoli P; Landi L; Rosati G; Ravaioli A; Cantore M; Di Fabio F; Aitini E; Marchet A;
Ann Oncol; 2014 Jul; 25(7):1373-1378. PubMed ID: 24728035
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.
Kim JA; Lee J; Han B; Park SH; Park JO; Park YS; Lim HY; Kang WK
Cancer Chemother Pharmacol; 2011 Jul; 68(1):177-84. PubMed ID: 20878159
[TBL] [Abstract][Full Text] [Related]
6. Quality of life of older adult patients receiving docetaxel-based chemotherapy triplets for esophagogastric adenocarcinoma: a randomized study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Kripp M; Al-Batran SE; Rosowski J; Pauligk C; Homann N; Hartmann JT; Moehler M; Hofheinz RD
Gastric Cancer; 2014 Jan; 17(1):181-7. PubMed ID: 23455717
[TBL] [Abstract][Full Text] [Related]
7. Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial.
Curran D; Pozzo C; Zaluski J; Dank M; Barone C; Valvere V; Yalcin S; Peschel C; Wenczl M; Goker E; Bugat R
Qual Life Res; 2009 Sep; 18(7):853-61. PubMed ID: 19568958
[TBL] [Abstract][Full Text] [Related]
8. Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival.
Kang EJ; Im SA; Oh DY; Han SW; Kim JS; Choi IS; Kim JW; Kim YJ; Kim JH; Kim TY; Lee JS; Bang YJ; Lee KW
Gastric Cancer; 2013 Oct; 16(4):581-9. PubMed ID: 23266882
[TBL] [Abstract][Full Text] [Related]
9. Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin.
Hubner RA; Cubillo A; Blanc JF; Melisi D; Von Hoff DD; Wang-Gillam A; Chen LT; Becker C; Mamlouk K; Belanger B; Yang Y; de Jong FA; Siveke JT
Eur J Cancer; 2019 Jan; 106():24-33. PubMed ID: 30458340
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma.
Loupakis F; Masi G; Fornaro L; Vasile E; Allegrini G; Fontana E; Granetto C; Salvatore L; Mentuccia L; Andreuccetti M; Cortesi E; Merlano M; Cascinu S; Falcone A
Cancer Chemother Pharmacol; 2010 Aug; 66(3):559-66. PubMed ID: 20237927
[TBL] [Abstract][Full Text] [Related]
11. Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by combination of oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI) in metastatic gastric cancer: results of a phase II trial.
Dalla Chiesa M; Tomasello G; Buti S; Rovere RK; Brighenti M; Lazzarelli S; Donati G; Passalacqua R
Cancer Chemother Pharmacol; 2011 Jan; 67(1):41-8. PubMed ID: 20204366
[TBL] [Abstract][Full Text] [Related]
12. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard.
Saltz LB; Douillard JY; Pirotta N; Alakl M; Gruia G; Awad L; Elfring GL; Locker PK; Miller LL
Oncologist; 2001; 6(1):81-91. PubMed ID: 11161231
[TBL] [Abstract][Full Text] [Related]
13. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803.
Bouché O; Raoul JL; Bonnetain F; Giovannini M; Etienne PL; Lledo G; Arsène D; Paitel JF; Guérin-Meyer V; Mitry E; Buecher B; Kaminsky MC; Seitz JF; Rougier P; Bedenne L; Milan C;
J Clin Oncol; 2004 Nov; 22(21):4319-28. PubMed ID: 15514373
[TBL] [Abstract][Full Text] [Related]
14. Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study.
Roy A; Cunningham D; Hawkins R; Sörbye H; Adenis A; Barcelo JR; Lopez-Vivanco G; Adler G; Canon JL; Lofts F; Castanon C; Fonseca E; Rixe O; Aparicio J; Cassinello J; Nicolson M; Mousseau M; Schalhorn A; D'Hondt L; Kerger J; Hossfeld DK; Garcia Giron C; Rodriguez R; Schoffski P; Misset JL
Br J Cancer; 2012 Jul; 107(3):435-41. PubMed ID: 22767144
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of a biweekly regimen of fluorouracil and leucovorin plus irinotecan in patients with previously untreated advanced gastric cancer.
Rosati G; Cordio S; Caputo G; Condorelli S; Germano D; Mattina M; Amadio P; Reggiardo G; Manzione L
J Chemother; 2007 Oct; 19(5):570-6. PubMed ID: 18073157
[TBL] [Abstract][Full Text] [Related]
16. A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5-fluorouracil and folinic acid regimens as first-line therapy for advanced colorectal cancer.
Bouzid K; Khalfallah S; Tujakowski J; Piko B; Purkalne G; Plate S; Padrik P; Serafy M; Pshevloutsky EM; Boussard B;
Ann Oncol; 2003 Jul; 14(7):1106-14. PubMed ID: 12853354
[TBL] [Abstract][Full Text] [Related]
17. Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741.
Delaunoit T; Goldberg RM; Sargent DJ; Morton RF; Fuchs CS; Findlay BP; Thomas SP; Salim M; Schaefer PL; Stella PJ; Green E; Mailliard JA
Cancer; 2004 Nov; 101(10):2170-6. PubMed ID: 15470715
[TBL] [Abstract][Full Text] [Related]
18. Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase II-III randomized trial.
Comella P; De Vita F; Mancarella S; De Lucia L; Biglietto M; Casaretti R; Farris A; Ianniello GP; Lorusso V; Avallone A; Cartenì G; Leo SS; Catalano G; De Lena M; Comella G
Ann Oncol; 2000 Oct; 11(10):1323-33. PubMed ID: 11106123
[TBL] [Abstract][Full Text] [Related]
19. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group.
Ajani JA; Moiseyenko VM; Tjulandin S; Majlis A; Constenla M; Boni C; Rodrigues A; Fodor M; Chao Y; Voznyi E; Awad L; Van Cutsem E;
J Clin Oncol; 2007 Aug; 25(22):3210-6. PubMed ID: 17664468
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy for advanced gastric cancer.
Wagner AD; Unverzagt S; Grothe W; Kleber G; Grothey A; Haerting J; Fleig WE
Cochrane Database Syst Rev; 2010 Mar; (3):CD004064. PubMed ID: 20238327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]